ESC Professional Premium Access

Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

Congress Session

About the speakers

Mr Thomas Michaeli

Mannheim (Germany)
1 presentation
0 follower

Mr Daniel Tobias Michaeli

University Medical Centre of Mannheim, Mannheim (Germany)
1 presentation
0 follower

5 more presentations in this session

Correlation of lipoprotein (a) with parameters of lipid profile and other cardiovascular risk factors in patients with familial combined hyperlipidemia

Speaker: Doctor I. Andrikou (Athens, GR)

Thumbnail

Recurrent atherosclerotic cardiovascular disease events preventable with guideline recommended lipid-lowering treatment following myocardial infarction

Speaker: Doctor R. Rosenson (New York, US)

Thumbnail

Simulation of bempedoic acid in the lipid-lowering treatment pathway using the European contemporary SANTORINI cohort of high- and very high-risk patients

Speaker: Doctor A. Bilitou (Munich, DE)

Thumbnail

PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study

Speaker: Doctor C. Basile (Naples, IT)

Thumbnail

Worldwide comparative efficacy of nutraceuticals on lipid profile. an updated systematic review and network meta-analysis

Speaker: Doctor T. Osadnik (Zabrze, PL)

Thumbnail

Access the full session

Lipids - Drug therapy 1

Speakers: Mr T. Michaeli, Mr D. Michaeli, Doctor I. Andrikou, Doctor R. Rosenson, Doctor A. Bilitou...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk